NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales. This ruling means that there will be a ...
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance. The cost-effectiveness body said ...
Bristol Myers’ BMY CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in 2025. Breyanzi is ...
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results